Mechanism of Action
Emgality is a CGRP binding antibody studied for episodic cluster headache1
Emgality is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor1
There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.1
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.